Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
357 stopped studies mapped to Malignant Glioma and descendants · 90% state a reason
Over the 357 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00730262 | Efficacy Study of TLN-4601 in Patients With Recurring Glioblastoma Multiforme | Phase 2 | terminated | Aug 8, 2008 | Thallion Pharmaceuticals | Lack of efficacy | Efficacy / futility |
| NCT00376103 | Radiation Boost for Newly Diagnosed Glioblastoma Multiforme | Phase 1 / Phase 2 | terminated | Sep 14, 2006 | Methodist Healthcare - Memphis | Loss of funding from sponsor | Funding |
| NCT00548938 | Gliadel Wafer, Temozolomide and Radiation Therapy for Newly Diagnosed GBM | Phase 2 | terminated | Oct 24, 2007 | Methodist Healthcare - Memphis | Principal Investigator has left the institution | Investigator |
| NCT00904852 | Safety Study of the Combination of Tandutinib With Temozolomide and Bevacizumab After… | Phase 1 | withdrawn | May 20, 2009 | Millennium Pharmaceuticals, Inc. | not stated | Not stated |
| NCT00365222 | Phase II Study of Temozolomide in Newly Diagnosed Glioblastoma | Phase 2 | terminated | Aug 17, 2006 | H. Lee Moffitt Cancer Center and Research Institute | IRB Study Closure | Other (stated, no rule matched) |
| NCT00083447 | Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With… | Phase 3 | withdrawn | May 26, 2004 | Xenova Biomedix | This study has been withdrawn because the drug would not meet trial criteria for efficacy | Efficacy / futility |
| NCT00115453 | Boron Neutron Capture Therapy (BNCT) as Treatment of Glioblastoma | Phase 1 / Phase 2 | terminated | Jun 23, 2005 | Boneca Corporation | Slow accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Dec 30, 2009source: clinicaltrials